Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Licensing Agreements
Innogenetics to distribute AdnaGen's CE-marked kits for breast and colon cancer in Europe
February 27th, 2007
Innogenetics, NV, and AdnaGen, AG, announced that they have entered into an exclusive European distribution agreement for AdnaGen's proprietary CE-certified diagnostics, the AdnaTest products for breast and colon cancer. The tests are based on the selection of circulating tumor cells from blood and subsequent detection of tumor markers. In parallel, Innogenetics also concluded a feasibility agreement to convert the current gel-based AdnaTest products into an in vitro multiplex platform and an option and exclusive license agreement to commercialize these new multiplex tests worldwide. Cancer diagnostics is a fast-evolving and rapidly growing segment...
Source: Cancer Weekly (2007-02-27)
|
